"Anecdotal evidence (published in Reader�s Digest) suggests Sanofi-Synthelabo�s drug rimonabant is very effective. In an article about weight loss, it was mentioned that a patient participating in phase III trials had lost 75 pounds after failing on many diets previously. It quoted the director of the trial program as saying that he was bound by a non-disclosure agreement and could not give details on the drug that was being investigated. However, it was possible to determine that the drug being investigated was rimonabant. Under development by Sanofi-Synthelabo, rimonabant is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. The drug, which has progressed to phase III development, works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endogenous cannabinoids, such as anadamide, increases appetite. It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction.
Sanofi-Synthelabo worked on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.....more"
BTW, Yahoo apparently removes messages with links in them. You can see the original commentary from the Investor�s Economic Resources site by putting �Investor�s Economic Resources� in Google or by Just putting investorsresources.bravehost.com in your browser URL , just cut and paste: investorsresources.bravehost.com ,no �www� is needed